Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 94
Inquire Before Buying

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 11, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 3 molecules, respectively.

Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).

- The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cervical Intraepithelial Neoplasia (CIN) - Overview
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
Bioleaders Corp
CEL-SCI Corp
Genexine Inc
Inovio Pharmaceuticals Inc
IRX Therapeutics Inc
PDS Biotechnology Corp
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
THEVAX Genetics Vaccine USA Inc
Transgene SA
Vaccibody AS
Vaxart Inc
Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles
ABI-1968 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSILSB-710c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLBL-101c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-188E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXI-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IRX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Multikine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-721689 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDS-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RKP-00156 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVGV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target E7 for HPV Associated Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-1016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VGX-3100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vvax-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products
Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones
Featured News & Press Releases
Feb 14, 2018: IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3
Dec 12, 2017: Vaccibody Announces Finalization of the Recruitment in the Phase IIa Part of Its Study With VB10.16 Immunotherapy for Patients With HPV16 Induced High Grade Lesions of the Cervix
Nov 29, 2017: Inovio's Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
Jun 21, 2017: Vaccibody Announces Positive Results From the 12-month Analysis of the Phase I Part of the Clinical Trial VB C-01 in Patients With High-grade Cervical Dysplasia
Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
Mar 23, 2017: Vaccibody Announces Vaccination Of First Patient In Its Phase IIA Study With VB10.16 Immunotherapy For Patients With HPV16 Induced High Grade Lesions Of The Cervix
Mar 02, 2017: Vaccibody Announces Approval Of Amendment Of IMPD Allowing To Start Of Expansion Phase In Its Phase I/IIa Study With VB10.16 Immunotherapy For Patients With HPV16 Induced High Grade Lesions Of The Cervix
Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed
Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016
Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as "Best Therapeutic Vaccine" by World Vaccine Congress
Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet
Apr 23, 2015: Global clinical development accelerated as cervical intraepithelial neoplasia therapeutic, GX-188E received expanded approval for Phase II from Europe
Mar 02, 2015: Genexines cervical intraepithelial neoplasia therapeutic "GX-188E" receives approval for Phase II in Europe
Jan 26, 2015: TheVax Genetics Vaccine Announces TVGV-1 Update
Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Bioleaders Corp, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corp, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine Inc, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by IRX Therapeutics Inc, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corp, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaxart Inc, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Sterile Injectables Market – Analysis By Molecule Type, Drug Type, Indication, Distribution Channel, By Region, By Country (2018 Edition): Forecast to 2023 -- Molecule Type (Biologic, Small Molecule), Drug Type (Monoclonal Antibody, Insulin, Vaccine, Fusion Protein, Immunoglobulin), Indication (Disorders – Oncological, Cardiovascular, Neurological, Infectious, Metabolic, Musculoskeletal), Channel (Hospital Pharmacy, Retail Pharmacy, E-commerce)
    Published: 25-Jun-2018        Price: US 2400 Onwards        Pages: 240
    Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Sterile Injectables Market by Molecule Type (Biologic, Small Molecule),  Drug Type (Monoclonal Antibody, Insulin, Vaccine, Fusion Protein, Immunoglobulin), Indication (Disorders – Oncological, Cardiovascular, Neurological, Infectious, Met......
  • Global Antidiabetic Drug Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 25-Jun-2018        Price: US 3480 Onwards        Pages: 134
    Diabetes mellitus is a kind of chronic comprehensive disease mainly caused by glucose metabolism disorder due to absolute or relative deficiency of insulin or decreased insulin sensitivity of target cells. The occurrence of type 2 diabetes mellitus is a combination of peripheral insulin resistance and ß cell dysfunction. the result of. When diabetes patients undergo diet and exercise therapy and diabetes care education, blood glucose control can still not reach the treatment goals, the need for ......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Antidiabetic Drug Market 2018, Forecast to 2023
    Published: 25-Jun-2018        Price: US 4880 Onwards        Pages: 134
    Diabetes mellitus is a kind of chronic comprehensive disease mainly caused by glucose metabolism disorder due to absolute or relative deficiency of insulin or decreased insulin sensitivity of target cells. The occurrence of type 2 diabetes mellitus is a combination of peripheral insulin resistance and ß cell dysfunction. the result of. When diabetes patients undergo diet and exercise therapy and diabetes care education, blood glucose control can still not reach the treatment goals, the need for ......
  • Global Insulin Drug and Delivery Technologies Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 25-Jun-2018        Price: US 3480 Onwards        Pages: 131
    Insulin is a protein hormone that is used as a medication to treat high blood glucose. This includes in diabetes mellitus type 1, diabetes mellitus type 2, gestational diabetes, and complications of  diabetes such as  diabetic ketoacidosis and hyperosmolar hyperglycemic states. It is also used along with glucose to treat high blood potassium levels. Typically it is given by injection under the skin, but some forms may also be used by injection into a vein or muscle. Scope of the R......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Insulin Drug and Delivery Technologies Market 2018, Forecast to 2023
    Published: 25-Jun-2018        Price: US 4880 Onwards        Pages: 130
    Insulin is a protein hormone that is used as a medication to treat high blood glucose. This includes in diabetes mellitus type 1, diabetes mellitus type 2, gestational diabetes, and complications of  diabetes such as  diabetic ketoacidosis and hyperosmolar hyperglycemic states. It is also used along with glucose to treat high blood potassium levels. Typically it is given by injection under the skin, but some forms may also be used by injection into a vein or muscle. Scope of the R......
  • Global EPA/DHA (Omega 3) Ingredients Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 25-Jun-2018        Price: US 3480 Onwards        Pages: 136
    IOI's range of MARIS OMEGA-3 ingredients helps making great products healthier, offering all the well-documented benefits of EPA and DHA for the cardiovascular and the nervous system. MARIS OMEGA-3 is manufactured "fresh as sushi", making use of innovative production technology to reach lowest oxidation levels. 100 % neutral in taste and smell, MARIS OMEGA-3 provides superior sensory properties and stability for food applications. Scope of the Report: This report focuses on......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) EPA/DHA (Omega 3) Ingredients Market 2018, Forecast to 2023
    Published: 25-Jun-2018        Price: US 4880 Onwards        Pages: 129
    IOI's range of MARIS OMEGA-3 ingredients helps making great products healthier, offering all the well-documented benefits of EPA and DHA for the cardiovascular and the nervous system. MARIS OMEGA-3 is manufactured "fresh as sushi", making use of innovative production technology to reach lowest oxidation levels. 100 % neutral in taste and smell, MARIS OMEGA-3 provides superior sensory properties and stability for food applications. Scope of the Report: This report focuses on......
  • Global Erythropoietin Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Jun-2018        Price: US 3480 Onwards        Pages: 136
    Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Erythropoietin Market 2018, Forecast to 2023
    Published: 23-Jun-2018        Price: US 4880 Onwards        Pages: 131
    Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs